Production of antibodies by modification of autonomous heavy chain variable domain via gene conversion
Summary
USPTO granted patent US12588664B2 to Crystal Bioscience Inc. on March 31, 2026. The patent covers transgenic animals engineered with B cells that use gene conversion for antibody diversification, involving functional immunoglobulin heavy chain genes and operably linked pseudogenes that donate sequence to enable diversification.
What changed
USPTO issued Patent No. US12588664B2 to Crystal Bioscience Inc. on March 31, 2026, for a transgenic animal system using gene conversion for antibody diversification. The patent includes 14 claims covering B cells with a functional immunoglobulin heavy chain gene encoding an autonomous heavy chain variable domain and a plurality of pseudogenes operably linked to donate sequence by gene conversion. The system enables upstream or downstream pseudogene donation to diversify antibody sequences.
This is a granted patent announcement with no compliance requirements or deadlines. Companies developing transgenic animal platforms for antibody discovery should review this patent to assess freedom-to-operate considerations. The patent has no enforcement deadlines, penalties, or required actions for general compliance teams.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
Grant US12588664B2 Kind: B2 Mar 31, 2026
Assignee
CRYSTAL BIOSCIENCE INC.
Inventors
William Don Harriman, Philip A. Leighton
Abstract
This disclosure provides, among other things, a transgenic animal that uses gene conversion for antibody diversification, comprising B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding an autonomous heavy chain (AHC) variable domain; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the AHC variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.
CPC Classifications
A01K 67/0275 A01K 2207/15 A01K 2227/30 A01K 2267/01 C07K 16/18 C07K 2317/22 C12N 15/8509
Filing Date
2019-06-05
Application No.
15734533
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.